The Principles of Engineering Immune Cells to Treat Cancer
By Wendell A. Lim, C. June. Cell, 2017
970 citations recorded by the source corpus.
Chimeric antigen receptor (CAR) T cells have proven that engineered immune cells can serve as a powerful new class of cancer therapeutics. Clinical experience has helped to define the major challenges that must be met to make engineered T cells a reliable, safe, and effective platform that can be deployed against a broad range of tumors. The emergence of synthetic biology approaches for cellular engineering is providing us with a broadly expanded set of tools for programming immune cells. We discuss how these tools could be used to design the next generation of smart T cell precision therapeutics.
Subfields: Immunology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/b77ab0dfe08ea9ab585b08cfcf1ca4111de2a78a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Molecular Biology
- Marinka Zitnik
- Kexin Huang
- Santrupti Nerli
- Jure Leskovec
- Cao Xiao
- Nikolaos G. Sgourakis
- Jimeng Sun
- Tianfan Fu
Citations in the corpus
- Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development (2021, background): “For example, the FDA recently approved engineering of T-cells using gene editing to treat patients with acute lymphoblastic leukemia (Lim & June 2017).”
- mRNA-based therapeutics: powerful and versatile tools to combat diseases (2022, background): “Generally, T cells acquire the ability to recognize tumor antigens via transgenic expression of a CAR or a high-affinity T cell receptor and subsequently exert therapeutic efficacy post infusion.(471) Adoptive transfer of autologous T cells is a promising cancer immunotherapy but requires a high qua”
- A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations (2018, methodology): “3 Each 2n − 1-mer input peptide yields n calls for each allele in the HLA haplotype, for each n = (9, 10) for MHCI and n = 15 for MHC-II.”
- Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics (2022, background): “While many strategies focus on modifying the native tumor microenvironment, an alternative strategy involves the direct infusion of engineered immune cells or cellular receptors into the patient via adoptive cellular therapy with the goal of increasing the number of effector cells that recognize tum”